Cover of: Recent advances in AIDS and Kaposi Read Online

Recent advances in AIDS and Kaposi"s sarcoma by International Workshop on AIDS/Kaposi"s Sarcoma (2nd 1986 Sorrento, Italy)

  • 737 Want to read
  • ·
  • 64 Currently reading

Published by Karger in Basel, New York .
Written in English


  • AIDS (Disease) -- Congresses.,
  • Kaposi"s sarcoma -- Congresses.,
  • Acquired Immunodeficiency Syndrome -- congresses.,
  • Sarcoma, Kaposi"s -- congresses.

Book details:

Edition Notes

Includes bibliographies and index.

Statement2nd International Workshop on AIDS/Kaposi"s Sarcoma, Sorrento, June 2, 1986 ; volume editors, G. Giraldo ... [et al.].
SeriesAntibiotics and chemotherapy ;, vol. 38
ContributionsGiraldo, G.
LC ClassificationsRM260 .A55 vol. 38, RC607.A26 .A55 vol. 38
The Physical Object
Paginationviii, 196 p. :
Number of Pages196
ID Numbers
Open LibraryOL2374812M
ISBN 103805545126
LC Control Number87002992

Download Recent advances in AIDS and Kaposi"s sarcoma


  Kaposi’s sarcoma (KS) is the most common malignancy associated with HIV infection and is considered an AIDS defining condition by the US Centers of Disease Control Guidelines. Several advances in the treatment of AIDS-related KS have been achieved over the past few years, even though a gold standard therapy for KS has not yet been defined and Cited by: Recent advances in understanding Kaposi’s sarcoma-associated herpesvirus Nathan J. Dissinger 1 and Blossom Damania a, 1 1 Lineberger Comprehensive Cancer Center and Department of Microbiology & Immunology, University Cited by: 9. Kaposi sarcoma is an interesting soft tissue tumor occurring in several distinct populations with a variety of presentations and courses. In its most well-known form, Kaposi sarcoma occurs in patients with immunosuppression, such as those with acquired immunodeficiency syndrome (AIDs) or those undergoing immunosuppression due to an organ transplant. Initially described Author: Bradie N. Bishop, David T. Lynch. – Christian Hoffmann, Stefan Esser – Kaposi’s sarcoma (KS) is the most common malignancy in patients with HIV infection. In , the simultaneous occurrence of KS with pneumocystis pneumonias in young MSM led to the first description of AIDS.

Kaposi's sarcoma: Advances and perspectives Robert A. Schwartz, MD, MPH Newark, New Jersey Kaposi' s sarcoma (KS) is an unusual neoplasm that has proved to be an enigma in many ways since its original description by KaPosi in Cited by: Kaposi sarcoma (KS) is the most common cancer seen in HIV. This cancer is caused by the human herpes virus 8 (HHV-8), also known as Kaposi sarcoma-associated herpesvirus (KSHV). The virus can be spread by deep kissing, unprotected sex, and sharing needles. It also can be spread from mother to child. Kaposi's sarcoma (KS) is a type of cancer that can form masses in the skin, lymph nodes, or other organs. The skin lesions are usually purple in color. They can occur singularly, in a limited area, or be widespread. It may worsen either gradually or quickly. Lesions may be flat or raised. Human herpesvirus 8 (HHV8) is found in the lesions of all those who are ciation: /kæˈpoʊsiz/, /ˈkɑːpəsiz, ˈkæpə-/.   Kaposi sarcoma (KS) causes red or purple patches of tissue (lesions) to grow under the skin and in the lining of the mouth, nose, and throat. Lesions may also develop in the digestive tract, liver, or lungs. KS generally occurs in people with weakened immune systems. In people with HIV, KS is an AIDS-defining condition.

This page lists cancer drugs approved by the Food and Drug Administration (FDA) for Kaposi sarcoma. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries. Kaposi sarcoma is a disease in which malignant lesions (cancer) can form in the skin, mucous membranes, lymph nodes, and other organs. Kaposi sarcoma is a cancer that causes lesions (abnormal tissue) to grow in the skin; the mucous membranes lining the mouth, nose, and throat; lymph nodes; or other lesions are usually purple and are made of cancer cells, . The advent of highly active antiretroviral therapy (HAART) has lead to a substantial reduction in the prevalence, morbidity, and mortality associated with AIDS-related Kaposi's sarcoma. Similarly, concomitant advances in chemotherapy and supportive-care protocols have allowed for Kaposi's sarcoma to be managed more effectively in comparison with the pre-HAART by: Abstract. Kaposi’s sarcoma (KS) is the most common malignancy associated with human immunodeficiency virus-1 (HIV) infection.’ During the early years of the acquired immunodeficiency syndrome (AIDS) epidemic, KS was the presenting manifestation of AIDS in 10%% of HIV-infected homosexual men and 1%-2% of HIV-infected individuals from other Cited by: